1. 1,4-Dihydropyridines versus beta-blockers for hypertension: Are either safe for the heart?

   • Frans H. H. Leenen

   Editorial: Focus on Calcium Antagonists Pages: 397 - 402

2. Calcium channel antagonists in the modern era of coronary thrombolysis: Benefit or detriment?

   • John A. Foley
   • Richard C. Becker

   Editorial: Focus on Calcium Antagonists Pages: 403 - 407

3. Controversies concerning calcium antagonists

   • Paul R. Lichtlen

   Editorial: Focus on Calcium Antagonists Pages: 409 - 412

4. Calcium channel blocker debate: True lies?

   • Jonathan Leor
   • Alex Battler

   Editorial: Focus on Calcium Antagonists Pages: 413 - 415

5. Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals

   • Claudio Napoli
   • Massimo Chiariello
   • Giuseppe Ambrosio

   Pharmacology: New Aspects of Calcium Antagonists Pages: 417 - 424

6. Effects of felodipine on the ischemic heart: Insight into the mechanism of cytoprotection

   • R. Ferrari
   • A. Cargnoni
   • C. Ceconi

   Pharmacology: New Aspects of Calcium Antagonists Pages: 425 - 437

7. Calcium antagonists and endothelial function: Focus on nitric oxide and endothelin

   • Théophile Godfraind
   • Salvatore Salomone

   Pharmacology: New Aspects of Calcium Antagonists Pages: 439 - 446

8. Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia

   • Quadiri Timour
   • Bernard Bui-Xuan
   • Jean-François Aupetit

   Pharmacology: New Aspects of Calcium Antagonists Pages: 447 - 454

9. Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease

   • Lionel H. Opie

   Therapy: Should Calcium Antagonists Be Among the First-Line Drugs? Pages: 455 - 461

10. Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective

    • Curt D. Furberg
    • Bruce M. Psaty

    Therapy: Should Calcium Antagonists Be Among the First-Line Drugs? Pages: 463 - 466

11. The STONE study (Shanghai Trial of Hypertension in the Elderly): A meeting report

    Meeting Report: STONE Study Pages: 467 - 468

12. Effect of ACE inhibitors on endothelial dysfunction: Unanswered questions and implications for further investigation and therapy

    • Bertram Pitt

    Coronary Artery Disease: Editorial Pages: 469 - 473

13. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: Results of SHIPS (SHIga Pravastatin Study)

    • Yasuyuki Nakamura
    • Osamu Yamaoka
    • the SHIga Pravastatin Study (SHIPS) Group

    Statins and Restenosis Pages: 475 - 483

14. Five-year mortality after acute myocardial infarction in relation to previous history, level of initial care, complications in hospital, and medication at discharge

    • Johan Herlitz
    • Angela Bång
    • Björn W. Karlson

    Myocardial Infarction: Long Term Mortality Pages: 485 - 490